MX2009009851A - Conjugados de agonistas de oligomeros-opioides. - Google Patents

Conjugados de agonistas de oligomeros-opioides.

Info

Publication number
MX2009009851A
MX2009009851A MX2009009851A MX2009009851A MX2009009851A MX 2009009851 A MX2009009851 A MX 2009009851A MX 2009009851 A MX2009009851 A MX 2009009851A MX 2009009851 A MX2009009851 A MX 2009009851A MX 2009009851 A MX2009009851 A MX 2009009851A
Authority
MX
Mexico
Prior art keywords
oligomer
opioid agonist
agonist conjugates
water
soluble oligomer
Prior art date
Application number
MX2009009851A
Other languages
English (en)
Inventor
Jennifer Riggs-Sauthier
Bo-Liang Deng
Timothy Andrew Riley
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2009009851A publication Critical patent/MX2009009851A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Polyethers (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a compuestos que son químicamente modificados por unión covalente de un oligómero soluble en agua. Un compuesto de la invención, cuando se administra por cualquiera de un número de rutas e de administración, exhibe características que son diferentes de aquellas del compuesto no unido al oligómero soluble en agua.
MX2009009851A 2007-03-12 2008-03-12 Conjugados de agonistas de oligomeros-opioides. MX2009009851A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90638707P 2007-03-12 2007-03-12
PCT/US2008/003353 WO2008112288A2 (en) 2007-03-12 2008-03-12 Oligomer-opioid agonist conjugates

Publications (1)

Publication Number Publication Date
MX2009009851A true MX2009009851A (es) 2009-09-24

Family

ID=39590911

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009851A MX2009009851A (es) 2007-03-12 2008-03-12 Conjugados de agonistas de oligomeros-opioides.

Country Status (18)

Country Link
EP (4) EP3222293B1 (es)
JP (2) JP5420427B2 (es)
KR (1) KR101568428B1 (es)
CN (1) CN101646464B (es)
AU (1) AU2008226822B2 (es)
CA (1) CA2679479C (es)
CY (1) CY1117368T1 (es)
DK (1) DK2134371T3 (es)
ES (1) ES2534741T3 (es)
HR (1) HRP20150315T1 (es)
IL (1) IL200845A (es)
ME (1) ME02176B (es)
MX (1) MX2009009851A (es)
PL (1) PL2134371T3 (es)
PT (1) PT2134371E (es)
RS (1) RS53937B1 (es)
SI (1) SI2134371T1 (es)
WO (1) WO2008112288A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
JP5827123B2 (ja) * 2008-09-16 2015-12-02 ウェルズ ファーゴ バンク ナショナル アソシエイション 乱用の可能性が低いｐｅｇ化オピオイド
CN105503889B (zh) * 2009-07-21 2019-12-24 尼克塔治疗公司 低聚物-阿片样激动剂轭合物
MX2012000980A (es) * 2009-07-21 2012-06-12 Nektar Therapeutics Conjugados de agonistas de oligómeros-opioides.
US20130023553A1 (en) * 2010-01-12 2013-01-24 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects
EP2552998A4 (en) * 2010-03-30 2013-11-06 Spago Imaging Ab COMPACT, BRANCHED POLYETHYLENE GLYCOL DERIVATIVES
MX2013005677A (es) 2010-11-30 2013-09-26 Research In Motion Ltd Re-seleccion de celdas en un red de telecomunicacion celular.
AU2012336030B2 (en) 2011-11-07 2017-09-14 Nektar Therapeutics Compositions, dosage forms, and coadministration of an opioid agonist compound and an analgesic compound
US10525054B2 (en) 2011-11-07 2020-01-07 Inheris Biopharma, Inc. Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound
ES2651689T3 (es) * 2012-10-30 2018-01-29 Nektar Therapeutics Forma salina de alfa-6-mPEG6-O-hidroxicodona sólida como antagonista opioide y usos de la misma
JP6577943B2 (ja) * 2013-06-28 2019-09-18 ネクター セラピューティクス κオピオイド作動薬及びその使用
CN107019803B (zh) * 2016-01-29 2020-09-15 北京键凯科技股份有限公司 具有低成瘾作用的聚乙二醇化阿片样物质
CN107033154B (zh) * 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN108210933B (zh) * 2016-12-22 2021-05-04 北京键凯科技股份有限公司 一种地佐辛与聚乙二醇的结合物
US11091497B2 (en) * 2017-12-08 2021-08-17 The Rockefeller University Pyrano[3,4-b]pyrazine kappa opioid receptor ligands for treating addiction, pruritus, pain, and inflammation
WO2019189188A1 (ja) 2018-03-29 2019-10-03 日油株式会社 トリチル基含有単分散ポリエチレングリコールの精製方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2654756A (en) 1949-10-20 1953-10-06 Mallinckrodt Chemical Works Process of preparing codeinone, dihydrocodeinone, and dihydromorphinone
US2628962A (en) 1949-10-20 1953-02-17 Mallinckrodt Chemical Works Method for preparing dihydrocodeinone, dihydromorphinone, and codeinone
US2649454A (en) 1951-08-20 1953-08-18 Univ California Method for preparing dihydromorphinone, dihydrocodeinone, and dihydropseudocodeinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US5475019A (en) * 1993-02-08 1995-12-12 East Carolina University Method of treating anxiety-related disorders with 2-aminocycloaliphatic amide compounds
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
EP2236161A1 (en) * 2001-10-18 2010-10-06 Nektar Therapeutics Polymer conjugates of opioid antagonists
WO2003058367A1 (en) 2002-01-11 2003-07-17 Valquest Limited Flow mixer shuttle
DE60307998T2 (de) * 2002-02-22 2007-04-05 Bayer Pharmaceuticals Corp., West Haven Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
ATE444296T1 (de) * 2002-10-25 2009-10-15 Euro Celtique Sa Analoga und prodrugs von buprenorphin
ATE454169T1 (de) * 2003-03-13 2010-01-15 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
CN1925875A (zh) 2003-12-16 2007-03-07 尼克塔治疗亚拉巴马公司 化学改性的小分子
WO2008036980A1 (en) 2006-09-22 2008-03-27 Alltranz Inc. Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
CA2667259A1 (en) * 2006-11-07 2008-05-15 Nektar Therapeutics Al, Corporation Dosage forms and co-administration of an opioid agonist and an opioid antagonist

Also Published As

Publication number Publication date
CN101646464A (zh) 2010-02-10
EP2623123A1 (en) 2013-08-07
RS53937B1 (en) 2015-08-31
HRP20150315T1 (hr) 2015-04-24
JP5877403B2 (ja) 2016-03-08
ES2534741T3 (es) 2015-04-28
AU2008226822A1 (en) 2008-09-18
CY1117368T1 (el) 2017-04-26
EP2134371B1 (en) 2015-01-14
PT2134371E (pt) 2015-04-16
CA2679479A1 (en) 2008-09-18
SI2134371T1 (sl) 2015-04-30
PL2134371T3 (pl) 2015-06-30
AU2008226822B2 (en) 2013-08-01
JP2013151563A (ja) 2013-08-08
WO2008112288A2 (en) 2008-09-18
EP2620163A1 (en) 2013-07-31
EP3222293B1 (en) 2019-11-27
KR20090118952A (ko) 2009-11-18
ME02176B (me) 2015-10-20
IL200845A0 (en) 2010-05-17
EP2134371A2 (en) 2009-12-23
CN101646464B (zh) 2013-05-29
JP5420427B2 (ja) 2014-02-19
JP2010521466A (ja) 2010-06-24
WO2008112288A3 (en) 2008-12-24
DK2134371T3 (en) 2015-04-27
KR101568428B1 (ko) 2015-11-11
CA2679479C (en) 2015-10-06
EP3222293A1 (en) 2017-09-27
EP2620163B1 (en) 2017-05-03
IL200845A (en) 2015-08-31

Similar Documents

Publication Publication Date Title
MX2009009851A (es) Conjugados de agonistas de oligomeros-opioides.
MX2009009850A (es) Conjugados de inhibidor de oligomero-proteasa.
MX2010005813A (es) Conjugados oligomero-triciclicos.
WO2009099670A3 (en) Oligomer-cannabinoid conjugates
WO2009042064A3 (en) Oligomer-nucleoside phosphate conjugates
EA201101165A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ Toll-ПОДОБНЫХ РЕЦЕПТОРОВ
NZ743487A (en) Controlled-release cnp agonists with increased nep stability
CY1119826T1 (el) Θεραπευτικες συνθεσεις που περιεχουν μακιτεντανη
MX2017008215A (es) Conjugados de farmacos proteinas de union que comprenden derivados de antraciclina.
WO2007103288A3 (en) Engineered antibody drug conjugates
EA200801758A1 (ru) Лекарственные формы, устойчивые к самовольному изменению
MX2009004965A (es) Formas de dosificacion y co-administracion de un agonista de opioides y un antagonista de opioides.
BR112015018161A2 (pt) Conjugado de oligômeros antisense de lna, composição farmacêutica e uso de um conjugado de oligômeros antisense de lna
MX2009009597A (es) Derivados de amino-piridina como agonistas del receptor s1p1/edg1.
EA021377B9 (ru) Модуляторы толл-подобных рецепторов
MY149869A (en) Thiophene derivatives as s1p1/edg1 receptor agonists
HK1172845A1 (en) Novel pharmaceutical formulations against drug misuse
WO2008112286A3 (en) De novo synthesis of conjugates
ZA202001747B (en) Psma-targeting amanitin conjugates
WO2009058387A3 (en) Oligomer-nitroimidazole anti-infective conjugates
EA200900958A1 (ru) Препарат невирапина пролонгированного высвобождения
PT2155255E (pt) Composições que incluem um composto hidrofóbico e um conjugado de poliaminoácido
MX2011007940A (es) Conjugados de oligomero-fenotiazina.
WO2010033204A3 (en) Polymer conjugates of c-peptides
WO2009045539A3 (en) Peg-corticosteroid conjugates

Legal Events

Date Code Title Description
FG Grant or registration